EGFR and non-small cell lung carcinoma: The recent LUX-Lung 7 trial reported statistically significant benefits in progression-free survival in patients receiving afatinib compared to gefitinib as first-line treatment in patients with non-small cell lung cancer harboring EGFR-activating mutations (HR, 0.73; 95% CI, 0.57–0.95, p = 0.017) [23].